Search research articles
Contact Us
Filters
Showing results (81-90 of 92) with videos related to
Page
of 10
Sort By:
European Journal of Endocrinology
|
March 25, 2022
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
Steven G Waguespack, Alexander Drilon, Jessica J Lin, et al.
JCO Precision Oncology
|
August 12, 2021
<i>TERT</i> Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence
Yao Yu, Dan Fan, Xinmao Song, et al.
Thyroid : Official Journal of the American Thyroid Association
|
June 12, 2025
Long-Term Results of External Beam Radiation Therapy with or Without Concurrent Chemotherapy in Differentiated Thyroid Cancer
Justin Choi, Eric Sherman, Edward Christopher Dee, et al.
Thyroid : Official Journal of the American Thyroid Association
|
January 20, 2022
Enhancing Radioiodine Incorporation in <i>BRAF</i>-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial
Vatche Tchekmedyian, Lara Dunn, Eric Sherman, et al.
Cancer Cell
|
August 15, 2018
Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes
Ian Ganly, Vladimir Makarov, Shyamprasad Deraje, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 12, 2016
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522
Minh Tam Truong, Qiang Zhang, David I Rosenthal, et al.
JAMA Otolaryngology-- Head & Neck Surgery
|
January 11, 2024
Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update
Lindsay A Bischoff, Ian Ganly, Laura Fugazzola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
William D Tap, Arun S Singh, Stephen Patrick Anthony, et al.
International Journal of Cancer
|
October 15, 2019
Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer
Thomas H Beckham, Christian Barney, Erin Healy, et al.
The New England Journal of Medicine
|
August 27, 2020
Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid Cancers
Lori J Wirth, Eric Sherman, Bruce Robinson, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 92) with videos related to
Sort By:
Page
of 10
European Journal of Endocrinology
|
March 25, 2022
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
Steven G Waguespack, Alexander Drilon, Jessica J Lin, et al.
JCO Precision Oncology
|
August 12, 2021
<i>TERT</i> Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence
Yao Yu, Dan Fan, Xinmao Song, et al.
Thyroid : Official Journal of the American Thyroid Association
|
June 12, 2025
Long-Term Results of External Beam Radiation Therapy with or Without Concurrent Chemotherapy in Differentiated Thyroid Cancer
Justin Choi, Eric Sherman, Edward Christopher Dee, et al.
Thyroid : Official Journal of the American Thyroid Association
|
January 20, 2022
Enhancing Radioiodine Incorporation in <i>BRAF</i>-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial
Vatche Tchekmedyian, Lara Dunn, Eric Sherman, et al.
Cancer Cell
|
August 15, 2018
Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes
Ian Ganly, Vladimir Makarov, Shyamprasad Deraje, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 12, 2016
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522
Minh Tam Truong, Qiang Zhang, David I Rosenthal, et al.
JAMA Otolaryngology-- Head & Neck Surgery
|
January 11, 2024
Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update
Lindsay A Bischoff, Ian Ganly, Laura Fugazzola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
William D Tap, Arun S Singh, Stephen Patrick Anthony, et al.
International Journal of Cancer
|
October 15, 2019
Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer
Thomas H Beckham, Christian Barney, Erin Healy, et al.
The New England Journal of Medicine
|
August 27, 2020
Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid Cancers
Lori J Wirth, Eric Sherman, Bruce Robinson, et al.
Page
of 10